1
|
Abstract
BackgroundThe approval of biosimilars requires pharmacokinetic studies to prove that there are no clinically significant differences to the originator molecule. These studies are also used to extrapolate additional indications and for different populations including paediatrics. Literature is lacking for the efficacy and safety of biosimilars for paediatric rheumatology conditions. Amgevita, a biosimilar of adalimumab, was approved for use in Singapore on 31 July 2019. It was used in KK Women’s and Children’s hospital (KKH), Singapore from 1 September 2020.ObjectivesTo report the safety and efficacy of adalimumab biosimilar in children at our centre.MethodsThis is an ongoing prospective, IRB-approved, observation study in a paediatric rheumatology clinic sited within KKH, a tertiary children’s hospital. Patients were reviewed in clinic to determine the need to initiate adalimumab (Amgevita), and completed pre-biologic screening to assess suitability to start. Patients were included if they received minimum 1 dose of adalimumab biosimilar. Safety parameters tracked: allergy, including urticaria, anaphylaxis, severe injection site reactions, rate of new onset infections requiring hospitalization and reactivation of latent infections (e.g., tuberculosis or herpes zoster). Adverse reactions were graded according to CTCAE v5.0. Efficacy parameters were tracked for patients with juvenile idiopathic arthritis (JIA) included JADAS27, JADAS71 and JSpADA.ResultsFrom 1 September 2020 to 31 October 2021, a total of 187 of 20mg syringes and 1403 pre-filled 40mg pens were dispensed to 117 paediatric rheumatology patients. Mean age was 14.9 years, 53.9% were male, 70.9% were Chinese and ethesitis-related arthritis (46.1%) was the most common indication. There were 68 (58.1%) biologic naïve patients. Two patients experienced injection-site urticaria which prompted discontinuation (grade 2). One patient reported initial injection site soreness which resolved spontaneously (grade 1). One patient developed latent tuberculosis requiring inpatient management and temporary interruption in adalimumab therapy (grade 3). No other adverse events were reported. Efficacy data was available for 96 patients. Median scores at baseline and at 3-months and 6-months are presented in Table 1.Table 1.Summary of paediatric patients initiated on adalimumab biosimilar (Amgevita)Diagnosis, n (%)Enthesitis related arthritisOf which HLA-B27 positive54 (46.1)44 (81.5)Polyarthritis21 (17.9)Extended or persistent oligoarthritis15 (12.8)Undifferentiated JIA6 (5.1)Psoriatic arthritis1 (0.8)Other indications21 (17.9)Concomitant DMARDs, n (%)Methotrexate50 (42.7)Sulfasalazine37 (31.6)*Efficacy, Median (range)Biologic naïveNot biologic naïveMonth number036036JADAS272(0-21.6)0(0-8.5)0(0-6.05)2(0-10.6)0(0-8.4)0(0-12.2)JADAS712(0-27.8)0(0-12.0)0(0-6.08)2(0-10.6)0(0-8.4)0(0-12.2)JSpADA0.25(0-3.5)0(0-1.0)0(0-1.0)0.5(0-1.5)0(0-0.5)0(0-2.0)DMARDs: Disease modifying anti-rheumatic drugs; JADAS: Juvenile Arthritis Disease Activity Score; JSpADA: Juvenile spondyloarthritis disease activity. *Efficacy data only for patients with juvenile idiopathic arthritisConclusionWe report our 14-month experience of using adalimumab biosimilar in a pediatric rheumatology population. Majority of the patients did not report major adverse reactions. Majority of JIA patients responded well when initiated on adalimumab (Amgevita). Rheumatologists should continually monitor patients for latent infections after prescribing biologics including biosimilars.References[1]Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. FDA website. Apr 2015. https://www.fda.gov/media/82647/download. Accessed 28 Dec 2021.[2]De Cock D, Kearsley-Fleet L, Baildam E, Beresford MW, et al. Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in aReal-World Setting in the United Kingdom [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).Disclosure of InterestsNone declared
Collapse
|
2
|
Childhood-onset systemic lupus erythematosus in Singapore: clinical phenotypes, disease activity, damage, and autoantibody profiles. Lupus 2015; 24:998-1005. [DOI: 10.1177/0961203315584413] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Accepted: 04/07/2015] [Indexed: 01/01/2023]
Abstract
Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease characterized by immune dysregulation affecting patients less than 18 years old. One-fifth of SLE cases are diagnosed during childhood. cSLE presents differently from adults and has a more severe and aggressive course. We describe the clinical and antibody profiles in our cSLE Singapore cohort. All cSLE patients who satisfied the 1997 American College of Rheumatology diagnostic criteria were captured in our lupus registry from January 2009 to January 2014. Data including demographic, cumulative clinical, serologic data, and damage indices were collected. Adjusted mean SLEDAI-2K (AMS) was used to summarize disease activity over multiple visits. Cluster analysis using non-hierarchical K-means procedure was performed on eight selected antibodies. The 64 patients (female:male ratio 5:1; Chinese 45.3%, Malay 28.1%, Indian 9.4%, and other races 17.2%) had a mean onset age of 11.5 years (range 2.1–16.7) and mean age at diagnosis was 11.9 years (range 2.6–18.0). Our study demonstrated differences in clinical manifestations for which hematologic involvement was the most common manifestation with less renal disease and uncommon neurologic manifestation as compared to other cSLE cohorts reported in our region. Antibody clusters were identified in our cohort but their clinical association/discrimination and outcome prediction required further validation study. Outcomes of our cohort in regard to disease activity after therapy and organ damages were comparable if not better to other cSLE cohorts elsewhere. Steroid-related damage, including symptomatic multifocal avascular necrosis and cataract, were not uncommon locally. Infection remains the major cause of death for the continent. Nevertheless, the five year survival rate of our cohort (98.4%) was high.
Collapse
|
3
|
SAT0471 Pediatric Rheumatology in Southeast Asia: Juvenile Idiopathic Arthritis in Singapore. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
AB0689 Comparison of pvas scores with mra findings of continued activity in singaporean children with takayasu arteritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.3011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|